Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for increasingly sustained human-to-human transmission of subclade Ia

View ORCID ProfileTony Wawina-Bokalanga, Sydney Merritt, Eddy Kinganda-Lusamaki, Daan Jansen, Megan Halbrook, Elisabeth Pukuta-Simbu, Áine O’Toole, Emmanuel Hasivirwe Vakaniaki, Rilia Ola-Mpumbe, Papy Kwete-Mbokama, Prince Akil-Bandali, Cris Kacita, Ange Ponga-Museme, Nelson Mapenzi-Kashali, Adrienne Amuri-Aziza, Olivier Tshiani-Mbaya, Princesse Paku-Tshambu, Pedro HLF Dantas, Tessa de Block, Emmanuel Lokilo, Chloé Muswamba, Jean-Claude Makangara-Cigolo, Gradi Luakanda, Christian Ngandu, David J. Kelvin, Catherine Pratt, Ahidjo Ayouba, Sofonias Tessema, Nicaise Ndembi, Antonio Mauro Rezende, Eric Delaporte, Dieudonné Mwamba, Lorenzo Subissi, View ORCID ProfileLaurens Liesenborghs, Nicole A. Hoff, Martine Peeters, Nicola Low, Steve Ahuka-Mundeke, Jean-Jacques Muyembe-Tamfum, Anne W. Rimoin, View ORCID ProfileJason Kindrachuk, Koen Vercauteren, Andrew Rambaut, Placide Mbala-Kingebeni
doi: https://doi.org/10.1101/2024.11.15.24317404
Tony Wawina-Bokalanga
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tony Wawina-Bokalanga
  • For correspondence: tonywawinab{at}yahoo.fr jason.kindrachuk{at}umanitoba.ca mbalaplacide{at}gmail.com
Sydney Merritt
4Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eddy Kinganda-Lusamaki
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
5TransVIHMI, Université de Montpellier, INSERM, IRD, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daan Jansen
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Halbrook
4Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Pukuta-Simbu
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Áine O’Toole
6Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Hasivirwe Vakaniaki
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rilia Ola-Mpumbe
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Papy Kwete-Mbokama
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prince Akil-Bandali
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cris Kacita
7Institut National de Santé Publique (INSP), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ange Ponga-Museme
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nelson Mapenzi-Kashali
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne Amuri-Aziza
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Tshiani-Mbaya
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Princesse Paku-Tshambu
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro HLF Dantas
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tessa de Block
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Lokilo
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chloé Muswamba
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Makangara-Cigolo
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
8Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gradi Luakanda
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Ngandu
7Institut National de Santé Publique (INSP), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Kelvin
9Department of Microbiology and Immunology, Faculty of Medicine. Dalhousie University, Halifax, NS, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Pratt
10Biosurv International, Salisbury SP4 0DQ, England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahidjo Ayouba
5TransVIHMI, Université de Montpellier, INSERM, IRD, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofonias Tessema
11Africa Centers for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicaise Ndembi
11Africa Centers for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Mauro Rezende
12Instituto René Rachou, Fiocruz Minas, Belo Horizonte, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Delaporte
5TransVIHMI, Université de Montpellier, INSERM, IRD, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dieudonné Mwamba
7Institut National de Santé Publique (INSP), Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Subissi
13World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurens Liesenborghs
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
14Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurens Liesenborghs
Nicole A. Hoff
4Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Peeters
5TransVIHMI, Université de Montpellier, INSERM, IRD, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Low
15Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Ahuka-Mundeke
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Jacques Muyembe-Tamfum
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne W. Rimoin
4Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Kindrachuk
16Department of Medical Microbiology & Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason Kindrachuk
  • For correspondence: tonywawinab{at}yahoo.fr jason.kindrachuk{at}umanitoba.ca mbalaplacide{at}gmail.com
Koen Vercauteren
3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Rambaut
6Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Placide Mbala-Kingebeni
1Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
2Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Democratic Republic of the Congo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tonywawinab{at}yahoo.fr jason.kindrachuk{at}umanitoba.ca mbalaplacide{at}gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Monkeypox virus (MPXV) is endemic to the Democratic Republic of the Congo (DRC), and historically has been reported in rural, forested regions with limited household and primarily zoonotic transmission. With the emergence of subclade Ib and increasing reported human-to-human transmission of MPXV we sought to characterize both the epidemiologic and genomic characteristics of confirmed mpox cases in Kinshasa, DRC, following confirmed MPXV introduction in August 2023.

Methods This retrospective observational study leveraged demographic and case-investigation data, as well as biological samples, collected from suspected mpox cases in Kinshasa from January 2023 to September 2024 as part of routine national surveillance. Samples were tested at the Institut National de Recherche Biomédicale first by qPCR to confirm MPXV, and subsequently sequenced for genomic analysis for those samples with a cycle threshold value <31.

Findings Epidemiological characterization of all confirmed mpox cases in Kinshasa indicated two distinct periods of MPXV introduction and circulation: first, following the initial case in August 2023, self-limiting transmission chains of subclade Ia primarily among men. Case investigations from this period suggest human-human transmission. The second period is marked by the introduction of subclade Ib to the city and expanded co-circulation of both subclades – with Limete health zone reporting the most cases of both subclades. Of those samples sequenced, genomic analysis indicated that greater than 60% of mutations in both subclades were consistent with APOBEC3-driven mutations.

Interpretation These data suggest that as of July 2024, MPXV in Kinshasa has undergone an epidemiological shift with sustained human-to-human transmission and co-circulation of two distinct subclades. Additionally, high rates of APOBEC3-driven changes further support this shift towards human-to-human transmission. While sexual-contact transmission cannot be confirmed without further case investigation, these data highlight important changes in mpox dynamics which may better guide mpox mitigation and containment strategies in Kinshasa.

Evidence before this study Historically, human infections with Clade I monkeypox virus (MPXV) have been driven through zoonotic transmission with limited secondary transmission. However, sexual contact-mediated transmission of Clade I MPXV among a small cluster of cases was identified for the first time in Kwango Province, DRC, in mid-2023. We searched PubMed, bioRxiv, and medRxiv for articles published from database inception to 11 November 2024, with no language restrictions, using the terms “mpox, monkeypox, Congo Basin, Clade I, AND outbreak”. All articles were published from 2010, with the majority published from 2022-2024, and included reviews, case reports, and laboratory investigations. Early reports on mpox outbreaks demonstrated that most infections resulted from zoonotic transmission events and the risks of sustained human-to-human transmission were considered to be very low. Assessment of human-to-human transmission of MPXV in the DRC between 1970-1980 and 1981-1986 suggested that there was no evidence for changes in secondary attack rates. This included a study of 93 MPXV-infected individuals who became symptomatic following close contact with mpox patients from 1981-1986 in DRC. Here, 69 cases resulted from transmission during the first virus generation, 19 in the second generation, and five cases in both the third and fourth generation. During the 1996-1997 mpox outbreak in DRC, it was reported that 73% of cases had contact with an mpox patient. A study of Clade I mpox in the Republic of the Congo from April-July 2003 suggested that up to seven sequential virus generations had occurred during the outbreak and was supported by the clustering of cases, uniform intervals of cases, and prior exposure histories of the patients. High secondary attack rates were also reported during an outbreak of Clade I mpox from July-December 2013 in the DRC where transmissions within the community were estimated to be ≥7 virus generations. While these observations suggested potential increased patterns of human-to-human MPXV transmission, these continued to be linked to close, sustained contacts primarily within households and among caregivers. However, the first report of a cluster of mpox cases in DRC linked to sexual contacts in 2023 suggested that intimate contact, including through heterosexual and same-sex contacts, could result in Clade I MPXV transmission. Viral genome sequences isolated from this case cluster demonstrated the highest sequence similarity with a 2022 Clade I MPXV sequence from DRC. Subsequent investigation of surveillance data in South Kivu province, DRC, from September 2023 to January 2024 identified 241 suspected mpox cases that included sustained human-to-human transmission. Among PCR-confirmed mpox cases, the median age was 22 years with 29% of individuals identifying as sex workers. Genomic analysis identified a distinct clade I lineage, named as subclade Ib, with a predominance of APOBEC3 mutations. Rapid geographic expansion of subclade Ib has resulted in introduction of MPXV to multiple neighboring countries for the first time and including sustained chains of virus transmission, most notably in Burundi. Subclade Ia MPXV has undergone rapid and extensive geographic expansion in DRC since 2023. A recent longitudinal analysis of MPXV genomes from 2018-2024 demonstrated that all non-South Kivu Province sequences exhibited high genetic diversity, low incidences of APOBEC3 mutations as compared to subclade Ib, and likely resulted from multiple zoonotic introductions. Collectively, historic mpox case data and recent observations since 2023 have suggested that human mpox cases in DRC have been driven by zoonotic transmissions of subclade Ia and an increasing burden of sustained human-to-human transmissions of subclade Ib in Eastern DRC, with limited disease burden in Kinshasa.

Added value of this study This investigation demonstrates a shift in the epidemiology of subclade Ia group II MPXV outbreaks, which had previously been typified by multiple independent zoonotic introductions. Epidemiologic analysis indicated two distinct periods for the Kinshasa mpox outbreak - an initial period from August 2023 to June 2024 characterized by sporadic subclade Ia mpox case detections, and a second period from July 2024-October 2024 characterized by co-emergence of both subclade Ia and Ib. The majority of mpox cases were adult males. In contrast to historic observations, children <15 years were not the primary demographic overrepresented among the subclade Ia mpox cases with those aged 16–49 years accounting for 79% of cases in this study. This investigation sequenced samples from mpox-confirmed cases in Kinshasa, DRC, by generating 115 near-complete MPXV genomes accompanied by phylogenomic analysis. Our findings reveal an escalation of the Kinshasa mpox outbreak that includes the establishment of both subclade Ia (Group II) and subclade Ib MPXV. Subclade Ia introductions (n=11 samples belonging to 5 clusters within Group II) into Kinshasa were observed in 2023 and 2024 with limited local transmission chains. In this analysis, we estimate that 63% of mutations in subclade Ia and 66% of mutations in subclade Ib from MPXV genomes collected in Kinshasa were consistent with APOBEC3-driven changes, a hallmark of human-to-human transmission.

Implications of all the available evidence This study provides critical evidence for a rapid shift in subclade Ia MPXV epidemiology to include more sustained human-to-human transmission. While Clade I mpox cases have historically been linked to zoonotic transmissions, the recent emergence of subclade Ib in Eastern DRC coupled with our observations reported here for subclade Ia further complicate our understanding of Clade I MPXV transmission. These results have important public health implications for regional and international partners given Kinshasa’s role as an international travel hub and as the largest city on the continent. Observations of new sequences from Kwilu, Kwango, and Kongo-Central provinces (subclade Ia), as well as Kasaï, Tanganyika and Tshopo (subclade Ib), linked to Kinshasa genomes further increase concerns regarding the broader risks for subclade Ia expansion, including within sexual networks.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The project or effort depicted is sponsored in part by the Department of Defense Threat Reduction Agency (HDTRA1-21-1-0040). This work is also supported by the United States Department for Agriculture (USDA) Agriculture Research Service (ARS) (USDA ARS NACA number 20230048, grant number 58-3022-2-020). The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred. The Africa Pathogen Genomics Initiative helped acquiring and maintaining the sequencer; Agence Francaise de Developpement through the AFROSCREEN project (grant agreement CZZ3209, coordinated by ANRS-MIE Maladies infectieuses emergentes in partnership with Institut de Recherche pour le Developpement (IRD) and Pasteur Institute) for laboratory support and PANAFPOX project funded by ANRS-MIE; Belgian Directorate-general for Development Cooperation and Humanitarian Aid (DGD), the Department of Economy, Science, and Innovation of the Flemish government, the Research Foundation - Flanders (FWO, grant number G096222 N to L.L; the International Mpox Research Consortium (IMReC) through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813); US NIAID/NIH grant number U01AI151799 through Center for Research in Emerging Infectious Disease-East and Central Africa (CREID-ECA). We acknowledge the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z, ARTIC network).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Samples were collected as part of a routine countrywide mpox surveillance program and were exempt from informed consent procedures. Permission to use anonymized data from the mpox national surveillance activities for this report was granted by the Ethics Committee of the Kinshasa School of Public Health (ESP-UNIKIN, Number ESP/CE/05/2023).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • ↵# Jointly supervised

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted November 16, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for increasingly sustained human-to-human transmission of subclade Ia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for increasingly sustained human-to-human transmission of subclade Ia
Tony Wawina-Bokalanga, Sydney Merritt, Eddy Kinganda-Lusamaki, Daan Jansen, Megan Halbrook, Elisabeth Pukuta-Simbu, Áine O’Toole, Emmanuel Hasivirwe Vakaniaki, Rilia Ola-Mpumbe, Papy Kwete-Mbokama, Prince Akil-Bandali, Cris Kacita, Ange Ponga-Museme, Nelson Mapenzi-Kashali, Adrienne Amuri-Aziza, Olivier Tshiani-Mbaya, Princesse Paku-Tshambu, Pedro HLF Dantas, Tessa de Block, Emmanuel Lokilo, Chloé Muswamba, Jean-Claude Makangara-Cigolo, Gradi Luakanda, Christian Ngandu, David J. Kelvin, Catherine Pratt, Ahidjo Ayouba, Sofonias Tessema, Nicaise Ndembi, Antonio Mauro Rezende, Eric Delaporte, Dieudonné Mwamba, Lorenzo Subissi, Laurens Liesenborghs, Nicole A. Hoff, Martine Peeters, Nicola Low, Steve Ahuka-Mundeke, Jean-Jacques Muyembe-Tamfum, Anne W. Rimoin, Jason Kindrachuk, Koen Vercauteren, Andrew Rambaut, Placide Mbala-Kingebeni
medRxiv 2024.11.15.24317404; doi: https://doi.org/10.1101/2024.11.15.24317404
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for increasingly sustained human-to-human transmission of subclade Ia
Tony Wawina-Bokalanga, Sydney Merritt, Eddy Kinganda-Lusamaki, Daan Jansen, Megan Halbrook, Elisabeth Pukuta-Simbu, Áine O’Toole, Emmanuel Hasivirwe Vakaniaki, Rilia Ola-Mpumbe, Papy Kwete-Mbokama, Prince Akil-Bandali, Cris Kacita, Ange Ponga-Museme, Nelson Mapenzi-Kashali, Adrienne Amuri-Aziza, Olivier Tshiani-Mbaya, Princesse Paku-Tshambu, Pedro HLF Dantas, Tessa de Block, Emmanuel Lokilo, Chloé Muswamba, Jean-Claude Makangara-Cigolo, Gradi Luakanda, Christian Ngandu, David J. Kelvin, Catherine Pratt, Ahidjo Ayouba, Sofonias Tessema, Nicaise Ndembi, Antonio Mauro Rezende, Eric Delaporte, Dieudonné Mwamba, Lorenzo Subissi, Laurens Liesenborghs, Nicole A. Hoff, Martine Peeters, Nicola Low, Steve Ahuka-Mundeke, Jean-Jacques Muyembe-Tamfum, Anne W. Rimoin, Jason Kindrachuk, Koen Vercauteren, Andrew Rambaut, Placide Mbala-Kingebeni
medRxiv 2024.11.15.24317404; doi: https://doi.org/10.1101/2024.11.15.24317404

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (896)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3253)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4900)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (879)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (539)
  • Pediatrics (1297)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4193)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)